SGLT2 Inhibitors linked to reduced risk of Atrial Fibrillation in type 2 Diabetes
A new study published in the journal Diabetes, Obesity and Metabolism has found that sodium-glucose co-transporter-2 (SGLT2) inhibitors are associated with a reduced incidence of atrial fibrillation in patients with type 2 diabetes mellitus.










